Mackenzie Financial Corp Apellis Pharmaceuticals, Inc. Transaction History

Mackenzie Financial Corp

$71.1 Billion
Q4 2024

A detailed history of Mackenzie Financial Corp transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Mackenzie Financial Corp holds 36,358 shares of APLS stock, worth $945,308. This represents 0.0% of its overall portfolio holdings.

Number of Shares

36,358

Previous 36,358 -0.0%

Holding current value

$945,308

Previous $1.16 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$26.18 - $35.42 $238,944 - $323,278	-9,127 Reduced 20.07%	36,358 $1.16 Million
Q3 2024 Nov 13, 2024	BUY	$28.84 - $41.15 $1.08 Million - $1.55 Million	37,546 Added 472.93%	45,485 $1.31 Million
Q2 2024 Aug 14, 2024	SELL	$38.07 - $59.71 $878,731 - $1.38 Million	-23,082 Reduced 74.41%	7,939 $304,000
Q1 2024 May 10, 2024	SELL	$55.39 - $72.47 $579,600 - $758,326	-10,464 Reduced 25.22%	31,021 $1.82 Million
Q4 2023 Jan 30, 2024	BUY	$37.14 - $64.82 $1.54 Million - $2.69 Million	41,485 New	41,485 $2.48 Million
Q2 2023 Aug 03, 2023	SELL	$76.68 - $93.31 $586,985 - $714,288	-7,655 Reduced 43.34%	10,007 $911,000
Q1 2023 Apr 24, 2023	BUY	$46.59 - $66.96 $342,902 - $492,825	7,360 Added 71.44%	17,662 $1.16 Million
Q4 2022 Feb 14, 2023	SELL	$43.24 - $61.04 $1.55 Million - $2.19 Million	-35,849 Reduced 77.68%	10,302 $532,000
Q3 2022 Oct 07, 2022	BUY	$44.76 - $69.66 $1.4 Million - $2.18 Million	31,355 Added 211.92%	46,151 $3.15 Million
Q2 2022 Aug 10, 2022	BUY	$35.07 - $59.21 $376,967 - $636,448	10,749 Added 265.6%	14,796 $669,000
Q1 2022 May 13, 2022	BUY	$35.46 - $54.12 $143,506 - $219,023	4,047 New	4,047 $206,000

Others Institutions Holding APLS

# of Institutions

302

Shares Held

123M

Call Options Held

2.63M

Put Options Held

845K

View Full List

About Apellis Pharmaceuticals, Inc.

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $2.86B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

More about APLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mackenzie Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Mackenzie Financial Corp with notifications on news.

Account

Mackenzie Financial Corp Apellis Pharmaceuticals, Inc. Transaction History